DRG COVID-19 Diagnostics
SPECIFIC - SENSITIVE - PRECISE
DRG developed two SARS-CoV-2 Antibody assays and today we proudly can announce the launch of:
1. SARS-CoV-2 (RBD) Total Ab ELISA EIA-6154
ELISA for the qualitative and highly sensitive detection of total (IgA, IgM and IgG) antibodies against Coronavirus SARS-CoV-2 in serum and plasma.
2. SARS-CoV-2 (RBD) IgG ELISA - quantitative EIA-6150
ELISA for the quantitative and highly specific detection of human IgG antibodies against Coronavirus SARS-CoV-2 in human serum and plasma.
Calibrated against the 1st WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (human) NIBSC code: 20/136.
Intended Use / Clinical Application:
- Sensitive detection of prior virus infection (> 14 days after infection)
- Support epidemiological studies for SARS-CoV-2
- Monitor vaccination success
Especially for IgG-quantitative ELISA: Monitor vaccination efficiency
Especially for Total Ab ELISA: Support of diagnosis of COVID-19 disease, supplement of direct pathogen detection via RT-PCR or pulmonary CT-Scans
Benefits at a Glance:
- Tests detect neutralizing antibodies directed against Receptor Binding Domain (RBD) of spike protein of SARS-CoV-2
- Specificity 100% for SARS-CoV-2 (RBD) IgG ELISA - quantitative
- Sensitivity 100% for SARS-CoV-2 (RBD) Total Ab ELISA
- Perfect tool to monitor vaccination efficiency: SARS-CoV-2 (RBD) IgG
- No sample dilution necessary: SARS-CoV-2 (RBD) Total Ab
- Ready-to-use reagents included
- Tests are prepared for automation on open ELISA platforms
- Developed, validated and manufactured in Marburg, Germany
- EU: CE / IVD
